Millennium Management
SPRO icon

Millennium Management’s Spero Therapeutics SPRO Stock Holding History

Millennium Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-24,107
Closed -$56.2K – 6340
2025
Q4 		$56.2K Buy
+24,107
New +$56K ﹤0.01% 5721
2024
Q4 		– Sell
-32,172
Closed -$43.1K – 6436
2024
Q3 		$43.1K Sell
32,172
-66,346
-67% -$89K ﹤0.01% 5703
2024
Q2 		$128K Sell
98,518
-49,354
-33% -$74.4K ﹤0.01% 5259
2024
Q1 		$254K Sell
147,872
-985
-0.7% -$1.54K ﹤0.01% 5229
2023
Q4 		$219K Buy
148,857
+29,163
+24% +$34.8K ﹤0.01% 5138
2023
Q3 		$145K Sell
119,694
-254,156
-68% -$352K ﹤0.01% 5230
2023
Q2 		$542K Sell
373,850
-120,691
-24% -$207K ﹤0.01% 4483
2023
Q1 		$717K Sell
494,541
-381,857
-44% -$639K ﹤0.01% 4369
2022
Q4 		$1.52M Buy
876,398
+188,002
+27% +$351K ﹤0.01% 3796
2022
Q3 		$1.38M Buy
688,396
+373,753
+119% +$372K ﹤0.01% 4065
2022
Q2 		$233K Buy
314,643
+253,382
+414% +$737K ﹤0.01% 5552
2022
Q1 		$533K Buy
+61,261
New +$628K ﹤0.01% 5078
2021
Q2 		– Sell
-12,635
Closed -$186K – 7069
2021
Q1 		$186K Sell
12,635
-45,427
-78% -$799K ﹤0.01% 5517
2020
Q4 		$1.13M Sell
58,062
-72,512
-56% -$1.13M ﹤0.01% 3660
2020
Q3 		$1.46K Buy
130,574
+94,581
+263% +$1.12M ﹤0.01% 2851
2020
Q2 		$487K Buy
35,993
+21,938
+156% +$246K ﹤0.01% 3419
2020
Q1 		$114K Buy
14,055
+1,373
+11% +$12.1K ﹤0.01% 3532
2019
Q4 		$122K Buy
+12,682
New +$137K ﹤0.01% 3988
2018
Q2 		– Sell
-11,415
Closed -$163K – 4144
2018
Q1 		$163K Buy
+11,415
New +$138K ﹤0.01% 3408

Other funds holding SPRO

GP
GSK plc London $599M AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management's SPRO Position: Q1 2026 in Review

Millennium Management sold out of Spero Therapeutics (SPRO) in Q1 2026, closing a stake of 24,107 shares — an estimated $56.2K sold.

Millennium Management first reported a position in SPRO in Q1 2018 and held it in 19 quarters. The position peaked at $1.52M in Q4 2022. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

  • Millennium Management reported no remaining Spero Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Millennium Management sold 24,107 Spero Therapeutics shares in Q1 2026, an estimated $56.2K.
  • Millennium Management first reported a position in Spero Therapeutics in Q1 2018 and held it in 19 quarters.
  • Millennium Management's Spero Therapeutics position peaked at $1.52M in Q4 2022.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.